• Citer

Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge

par Jackisch, Christian;Cortazar, Patricia;Geyer Jr., Charles C.E.;Gianni, Luca;Gligorov, Joseph;Machackova, Zuzana;Perez, Edith A;Schneeweiss, Andreas;Tolaney, Sara S.M.;Untch, Michael;Wardley, Andrew;Piccart-Gebhart, Martine
Référence Cancer treatment reviews, 99, 102229
Publication Publié, 2021-09

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
Auteur:	Jackisch, Christian; Cortazar, Patricia; Geyer Jr., Charles C.E.; Gianni, Luca; Gligorov, Joseph; Machackova, Zuzana; Perez, Edith A; Schneeweiss, Andreas; Tolaney, Sara S.M.; Untch, Michael; Wardley, Andrew; Piccart-Gebhart, Martine
Informations sur la publication:	Cancer treatment reviews, 99, 102229
Statut de publication:	Publié, 2021-09
Sujet CREF:	Imagerie médicale, radiologie, tomographie
	Cancérologie
Mots-clés:	HER2-postive early breast cancer
	Neoadjuvant therapy
	Neratinib
	Pertuzumab
	T-DM1
	Trastuzumab
Note générale:	SCOPUS: re.j
Langue:	Anglais
Identificateurs:	urn:issn:0305-7372
	info:doi/10.1016/j.ctrv.2021.102229
	info:pii/S0305737221000773
	info:scp/85107715800